Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

doi:10.3390/microorganisms7080270

Review

. 2019 Aug 18;7(8):270.

doi: 10.3390/microorganisms7080270.

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Despoina Koulenti^{1

2}, Elena Xu¹, Isaac Yin Sum Mok¹, Andrew Song¹, Drosos E Karageorgopoulos³, Apostolos Armaganidis², Jeffrey Lipman^{1

4

5}, Sotirios Tsiodras³

Affiliations

¹ UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia. d.koulenti@uq.edu.au.
² 2nd Critical Care Department, Attikon University Hospital, 12462 Athens, Greece. d.koulenti@uq.edu.au.
³ 4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece.
⁴ Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, 4029 Brisbane, Australia.
⁵ Anesthesiology and Critical Care, Centre Hospitalier Universitaire De Nîmes (CHU), University of Montpellier, 30029 Nîmes, France.

PMID: 31426596
PMCID: PMC6723731
DOI: 10.3390/microorganisms7080270

Review

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Despoina Koulenti et al. Microorganisms. 2019.

. 2019 Aug 18;7(8):270.

doi: 10.3390/microorganisms7080270.

Authors

Despoina Koulenti^{1

2}, Elena Xu¹, Isaac Yin Sum Mok¹, Andrew Song¹, Drosos E Karageorgopoulos³, Apostolos Armaganidis², Jeffrey Lipman^{1

4

5}, Sotirios Tsiodras³

Affiliations

¹ UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia. d.koulenti@uq.edu.au.
² 2nd Critical Care Department, Attikon University Hospital, 12462 Athens, Greece. d.koulenti@uq.edu.au.
³ 4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece.
⁴ Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, 4029 Brisbane, Australia.
⁵ Anesthesiology and Critical Care, Centre Hospitalier Universitaire De Nîmes (CHU), University of Montpellier, 30029 Nîmes, France.

PMID: 31426596
PMCID: PMC6723731
DOI: 10.3390/microorganisms7080270

Abstract

Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.

Keywords: and omadacycline; besifloxacin; ceftaroline; ceftobiprole; dalbavancin; delafloxacin; gram-positive pathogens; multidrug-resistance; novel antibiotics; oritavancin; ozenoxacin; tedizolid; telavancin.

PubMed Disclaimer

Conflict of interest statement

Author J.L. reports: Advisory Board with Bayer and MSD and honorarium for lectures from Pfizer and MSD. All other authors (DK, EX, AS, IYSM, DEK, AA and ST) declare no competing interests.

Cited by

Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.
Sharma R, Sandrock CE, Meehan J, Theriault N. Sharma R, et al. Clin Drug Investig. 2020 Oct;40(10):947-960. doi: 10.1007/s40261-020-00953-z. Clin Drug Investig. 2020. PMID: 32889706 Free PMC article. Review.
QbD Based Formulation Development and Optimisation of Ozenoxacin Topical Nano-Emulgel and Efficacy Evaluation Using Impetigo Mice Model.
Ramireddy AR, Behara DK. Ramireddy AR, et al. AAPS PharmSciTech. 2024 Apr 22;25(5):90. doi: 10.1208/s12249-024-02805-x. AAPS PharmSciTech. 2024. PMID: 38649513
Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions.
Kakoullis L, Papachristodoulou E, Chra P, Panos G. Kakoullis L, et al. Antibiotics (Basel). 2021 Apr 10;10(4):415. doi: 10.3390/antibiotics10040415. Antibiotics (Basel). 2021. PMID: 33920199 Free PMC article. Review.
Analysis of changes in antibiotic resistance in the human body using an in vitro digestion model incorporating human gut microbiota.
Lee SY, Lee DY, Kang HJ, Yun SH, Mariano EJ, Lee J, Kim JH, Hur SJ. Lee SY, et al. Heliyon. 2023 May 16;9(5):e16128. doi: 10.1016/j.heliyon.2023.e16128. eCollection 2023 May. Heliyon. 2023. PMID: 37251864 Free PMC article.
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Dávila P, Iftimie S, Sequera S, Loeches B, Lopez-Cortés LE, Fariñas MC, Fernández-Roldan C, Javier-Martinez R, Muñoz P, Arenas-Miras MDM, Martínez-Marcos FJ, Miró JM, Herrero C, Bereciartua E, De Jesus SE, Pasquau J. Hidalgo-Tenorio C, et al. Ann Clin Microbiol Antimicrob. 2019 Oct 19;18(1):30. doi: 10.1186/s12941-019-0329-6. Ann Clin Microbiol Antimicrob. 2019. PMID: 31629409 Free PMC article.

See all "Cited by" articles

References

1. Li B., Webster T.J. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J. Orthop. Res. 2018;36:22–32. - PMC - PubMed
1. O’Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. 2014;20:1–16.
1. David M.Z., Dryden M., Gottlieb T., Tattevin P., Gould I.M. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: The shock of the new. Int. J. Antimicrob. Agents. 2017;50:303–307. - PubMed
1. Magiorakos A.P., Srinivasan A., Carey R., Carmeli Y., Falagas M., Giske C., Harbarth S., Hindler J., Kahlmeter G., Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. - PubMed
1. Khameneh B., Diab R., Ghazvini K., Bazzaz B.S.F. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb. Pathog. 2016;95:32–42. doi: 10.1016/j.micpath.2016.02.009. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Li B., Webster T.J. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J. Orthop. Res. 2018;36:22–32. - PMC - PubMed

[2] Li B., Webster T.J. Bacteria antibiotic resistance: New challenges and opportunities for implant-associated orthopedic infections. J. Orthop. Res. 2018;36:22–32. - PMC - PubMed

[3] O’Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. 2014;20:1–16.

[4] O’Neill J. Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. 2014;20:1–16.

[5] David M.Z., Dryden M., Gottlieb T., Tattevin P., Gould I.M. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: The shock of the new. Int. J. Antimicrob. Agents. 2017;50:303–307. - PubMed

[6] David M.Z., Dryden M., Gottlieb T., Tattevin P., Gould I.M. Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: The shock of the new. Int. J. Antimicrob. Agents. 2017;50:303–307. - PubMed

[7] Magiorakos A.P., Srinivasan A., Carey R., Carmeli Y., Falagas M., Giske C., Harbarth S., Hindler J., Kahlmeter G., Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. - PubMed

[8] Magiorakos A.P., Srinivasan A., Carey R., Carmeli Y., Falagas M., Giske C., Harbarth S., Hindler J., Kahlmeter G., Olsson-Liljequist B. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012;18:268–281. - PubMed

[9] Khameneh B., Diab R., Ghazvini K., Bazzaz B.S.F. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb. Pathog. 2016;95:32–42. doi: 10.1016/j.micpath.2016.02.009. - DOI - PubMed

[10] Khameneh B., Diab R., Ghazvini K., Bazzaz B.S.F. Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them. Microb. Pathog. 2016;95:32–42. doi: 10.1016/j.micpath.2016.02.009. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Affiliations

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Research Materials